Woodline Partners’s NextCure NXTC Stock Holding History

Woodline Partners’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,498	Closed	-$294K	–	1113
2026 Q1	$294K	Buy	+27,498	New	+$336K	﹤0.01%	1006
2022 Q2	–	Sell	-13,470	Closed	-$786K	–	860
2022 Q1	$786K	Sell	13,470 -49,530	-79%	-$3.1M	0.01%	490
2021 Q4	$4.54M	Buy	+63,000	New	+$5.27M	0.07%	293

Other funds holding NXTC

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Verdad Advisers Boston, Massachusetts $104M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Woodline Partners's NXTC Position: Q2 2026 in Review

Woodline Partners sold out of NextCure (NXTC) in Q2 2026, closing a stake of 27,498 shares — an estimated $294K sold.

Woodline Partners first reported a position in NXTC in Q4 2021 and held it in 3 quarters. The position peaked at $4.54M in Q4 2021. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

Woodline Partners reported no remaining NextCure position as of Q2 2026 after selling out during the quarter.
Woodline Partners sold 27,498 NextCure shares in Q2 2026, an estimated $294K.
Woodline Partners first reported a position in NextCure in Q4 2021 and held it in 3 quarters.
Woodline Partners's NextCure position peaked at $4.54M in Q4 2021.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.